


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Caroline DELATTRE et al.

Application No.: 10/757,505

Filing Date: January 15, 2004

Title: TOPICALLY APPLICABLE COSMETIC/DERMATOLOGICAL
COMPOSITIONS COMPRISING HYDROLASE
POLYPEPTIDES HAVING AMIDASE ACTIVITY AND/OR
PRODUCTS MODULATING THE ACTIVITY THEREOF



Group Art Unit: 1651

Examiner: Susan Emily Fernandez

Confirmation No.: 6320

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form
PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

Date: February 23, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Caroline DELATTRE et al.

Application No.: 10/757,505

Filed: January 15, 2004

For: TOPICALLY APPLICABLE
COSMETIC/DERMATOLOGICAL
COMPOSITIONS COMPRISING
HYDROLASE POLYPEPTIDES
HAVING AMIDASE ACTIVITY AND/OR
PRODUCTS MODULATING THE
ACTIVITY THEREOF



) MAIL STOP AMENDMENT

) Group Art Unit: 1651

) Examiner: Susan Emily Fernandez

) Confirmation No.: 6320

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

It is requested that the Examiner consider the documents listed on the accompanying Form PTO-1449. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents listed is enclosed. These documents were cited in a preliminary search report issued in connection with the corresponding French application. A copy of the French search report and an English translation thereof are enclosed.

The following remarks are offered with respect to the documents cited in the French search report:

FR 2357246 is in French and no English-language counterpart or English translation is available to applicants. This document discloses a pharmaceutical composition with anti-inflammatory and analgesic activity comprising the association of hydrolase, thyroxin, adrenalin and an excipient enhancing the cutaneous penetration and diffusion of the actives into the blood circulation. The amidases are mentioned in claim 2 as examples of hydrolases; however, all examples are related to glycosidases (examples: mucopolysaccharidase, alpha-chymotrypsine, hyaluronidase and alpha-amylase), which are distinct from hydrolases with amidasic function. Moreover, there is no mention of any pro-desquamating activity of said hydrolyases. Thus, this document does not teach or suggest

the instant regimes or regimens for promoting desquamation by applying hydrolases with amidasic activity and related applications.

The abstract of the article by Määttä et al. is classified as a general state of the art reference in the French search report. It refers to the link between aspartylglucosaminuria (AGU) and lack of aspartylglucosylaminase.

WO 96/24371 is also classified as a general state of the art reference in the French search report. It discloses multifunctional enzymes that can be derived from crustaceans or fish (examples: chymotrypsin, trypsin, elastase, collagenase and hydrolase).

This statement, Form PTO-1449 and accompanying papers are being submitted together with a response to a Restriction Requirement, before the first Office Action on the merits. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

As mentioned above, this Information Disclosure Statement contains information which is not in the English language but was cited in a search report by a foreign patent office in a counterpart foreign application. In accordance with MPEP § 609 III A(3), an English language version of the search report which indicates the degree of relevance found by the foreign office is being submitted herewith.

It is respectfully requested that the Examiner consider this statement and accompanying documents and other papers and return an Examiner-initialed copy of the accompanying Form PTO-1449 to the undersigned with the next official communication.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date February 23, 2005

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/757,505
Filing Date	January 15, 2004
First Named Inventor	Caroline DELATTRE et al.
Examiner Name	Susan Emily Fernandez
Attorney Docket Number	016800-583

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	2 357 246	A	FR	02-03-1978				X			
	96/24371	A	WO	08-15-1996				X			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	DATABASE MEDLINE on line, U.S. National Library of Medicine (NLM), Bethesda, MD, US, Määttä et al., Database accession no. NLM 8312372, abstract of BIOCHIMICA ET BIOPHYSICA ACTA., NETHERLANDS, February 22, 1994, vol. 1225, no. 3, pp. 264-270.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.